Peer-reviewed veterinary case report
Heart monitoring results during doxorubicin chemo in small dogs
By Tang, Y S & Wang, S L·Published in Veterinary journal (London, England : 1997)·2024·Institute of Veterinary Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Outcome of serial cardiac evaluations during doxorubicin-based chemotherapy in small- to medium-sized dogs with multicentric lymphoma.
- Species:
- dog
Plain-English summary
A group of small- to medium-sized dogs with multicentric lymphoma received doxorubicin, a chemotherapy drug, every four weeks as part of their treatment. Over the course of the treatment, the dogs underwent regular heart evaluations, including echocardiograms and electrocardiograms, to check for any heart problems. Thankfully, none of the dogs showed signs of heart damage or arrhythmias, indicating that the chemotherapy was well-tolerated in these dogs without pre-existing heart issues. Overall, the treatment was effective without causing significant heart-related side effects.
People also search for: dog lymphoma chemotherapy side effects · doxorubicin heart problems in dogs · small dog cancer treatment
Abstract
Doxorubicin is an anthracycline antitumor antibiotic with dose-dependent and cumulative cardiotoxicity. However, the necessity for serial cardiac evaluation is unknown in dogs without risk factors for dilated cardiomyopathy (DCM). This study aimed to investigate serial changes in echocardiographic and electrocardiographic measures in small- and medium-sized dogs after four doxorubicin doses. We included 17 dogs, weighting < 20 kg, with multicentric lymphoma. All dogs received doxorubicin over 30 min every 4 weeks as part of a multi-drug chemotherapy protocol. The average doxorubicin dose was 3.8 times per dog. Clinical cardiotoxicity was not observed during the monitoring period. The incidence of developing arrhythmia was not significantly associated with the number of doxorubicin doses received (P = 0.600). The development of valvular regurgitations and mitral regurgitation in these dogs was not significantly associated with the number of doxorubicin doses (P = 0.363 and P = 0.779, respectively). The other echocardiographic results were not significantly different between each evaluation. In conclusion, our results showed no significant cardiotoxicity under echocardiogram and electrocardiogram in small- and medium-sized dogs without risk factors for DCM after four doses of doxorubicin in a 30-minute infusion method.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/38750812/